Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Wednesday, 13 June 2007

CVS/Caremark Loses a Big One

Posted on 05:40 by Unknown
Sometimes history doesn’t repeat itself.

When the Blue Cross Blue Shield Association awarded the lucrative Federal Employee Program pharmacy benefit management services contract June 6, it made a surprising decision: splitting the contract into two parts, one to manage the retail pharmacy side of the network, and the other to provide mail service to the almost 4 million federal government employees, retirees and dependents covered by the BCBSA plan.

They let CVS Caremark keep the retail. But they gave the mail service back to Medco Health Solutions Inc. That is the arrangement that BCBSA had for most of the 1990s, until it decided three years ago to give Caremark the whole enchilada.

CVS Caremark says it is happy it will continue to provide retail services. Medco says it is happy to be back as the mail order provider. So everybody’s happy, right?

Hardly. The decision by BCBSA to split the contract again surprised most PBM analysts on Wall Street—and it definitely disappointed investors in CVS Caremark.

It also marks an ominous beginning for the newly merged CVS Caremark business. The big question surrounding the company is whether the marketplace will accept Caremark’s new status as a division of the retail chain giant CVS. (There is much more on the implications of the CVS/Caremark deal in the January issue of The RPM Report.)

And that’s where the historical parallels come in. The last time Caremark was involved in a big merger, it was the acquirer, buying the PBM Advance PCS. At the time of the deal, Caremark said it expected the acquisition would boost its bid for the FEP mail order business—and the company was awarded the contract soon after the deal closed.

There was another factor that may have played a role in that decision three years ago: Medco had just settled a Department of Justice investigation into its mail order pharmacy practices, which included claims that the company had falsified some of its reports to BCBSA under the Federal Employees Program.

It sure is nice of BCBSA to let bygones be bygones. But it is also a clear indication that the stand-alone PBM giants (all two of them, including Express Scripts Inc.) still have life left in them.
Email ThisBlogThis!Share to XShare to Facebook
Posted in CVS Caremark, pharmacy benefits | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Ventana Accepts $3.4 Billion
    Roche finally nabs its man. Or in this case, its diagnostics company. All it took was an extra $14.50 per share. From the companies' pre...
  • Merck: Embracing Externalization, From the Top Down
    Updated Below . One business magazine greeted the tenure of Dick Clark as Merck's new CEO in 2005 with the instruction to "say hel...
  • While You Were Coming Back
    It would be wrong for us not to mention the Red Sox in this space, the Boston nine having completed their three-game comback victory over th...
  • Unusual Suspects: If Pfizer Decides to Really Rattle the R&D Cages
    Yesterday, we listed a group of people -- we called them the usual suspects -- that we think Pfizer will try to woo if it ends up turning to...
  • Avandia and Rezulin: Parallels that Should Make GSK Nervous
    History doesn’t repeat itself but it does rhyme. That old Mark Twain saying must be making GlaxoSmithKline sweat as Avandia is starting to ...
  • Private Equity Goes Public
    One of the simplest metrics we have to measure interest in a company or industry is just how jammed the rooms are at the JP Morgan conferenc...
  • High Noon at Myogen
    Most VC meetings provide a feel-good story for the portfolio CEOs—usually a variation on the business resurrection theme. The Atlas Venture ...
  • While You Were Watching the Upsets
    This weekend we were in Cardiff for the Rugby World Cup quarterfinal between France and New Zealand, which saw France upsetting the favorite...
  • Deals of the Week: You Can't Always Get What You Want
    It's been a busy--and, for some, disheartening--week in biopharma land. Just three days after researchers disclosed that Vytorin , the h...
  • Sorry, I Still Don’t Get It
    Pfizer launched its first TV campaign for Exubera this past week in an attempt to breathe a little life into the stalled inhaled insulin br...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ▼  June (39)
      • Could've Seen That One Coming
      • Private Equity: Muscling in on Big Pharma at Biote...
      • Live from Paris: Roger's dealmaking overview
      • In Our Face
      • Welcome to Paris: take my drug ... Please
      • Roche to Ventana: We want you so bad
      • Good Things Come
      • Roche makes Ventana an offer it may or may not be ...
      • Big Week For the Bushes
      • Venture Debt in Europe: Opportunity Missed?
      • While You Were at ADA
      • Brailer's New Quest
      • The Wrong Man for This Job
      • Overheard at the London Stock Exchange Mediscience...
      • Preserving the Right to Advertise—No Matter How Du...
      • Sometimes the Bear Gets You: Coley Pharmaceuticals...
      • Why No More Roche-Genentechs?
      • Size Matters for Specialist Drugs, Too
      • The Other Surge
      • Should Some of these Butterflies Get Eaten?
      • While You Were Celebrating Father's Day ...
      • What Drug Makers Can Learn from Vaccines
      • Rimonabant’s Risky Business
      • Is FDA Killing Research?
      • Record VC dough for device makers
      • Israel’s Public Venture Market
      • CVS/Caremark Loses a Big One
      • Fat Chance for Rimonabant
      • Launching Alli
      • While You Were Watching the Finale
      • It must be two-for-one week on private biotechs
      • The Wisdom of Buybacks
      • PhRMA's DTC Verdict: it ain't broke, we're not gon...
      • R&D: Worth It Only When You Don’t Pay for It
      • Amgen buys Ilypsa for $420mm cash
      • Hi, I’m from Medtronic. My name is …
      • No Cure, No Pay
      • While You Were in the Cheap Seats
      • Jazz IPO Fails to Generate Buzz
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile